Literature DB >> 25702359

For how long should we use symptomatic therapies to treat people with Alzheimer disease?

Kenneth Rockwood.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25702359      PMCID： PMC4304579          DOI： 10.1177/070674371405901201

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


× No keyword cloud information.
  12 in total

1.  Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials.

Authors:  K Rockwood; C MacKnight
Journal:  Neuroepidemiology       Date:  2001-05       Impact factor: 3.282

Review 2.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.

Authors:  K Rockwood
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

3.  Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.

Authors:  Kenneth Rockwood; Sherri Fay; Pamela Jarrett; Elissa Asp
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

4.  The importance of measuring executive function when studying the effects of cognition-enhancing agents.

Authors:  Kenneth Rockwood
Journal:  Ann Intern Med       Date:  2008-09-02       Impact factor: 25.391

Review 5.  Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.

Authors:  David B Hogan
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

Review 6.  Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.

Authors:  Colleen J Maxwell; Kathryn Stock; Dallas Seitz; Nathan Herrmann
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

7.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 8.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Authors:  Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; Mark Oremus
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

Review 9.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

10.  Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4).

Authors:  Serge Gauthier; Christopher Patterson; Howard Chertkow; Michael Gordon; Nathan Herrmann; Kenneth Rockwood; Pedro Rosa-Neto; Jean-Paul Soucy
Journal:  Can Geriatr J       Date:  2012-12-04
View more
  4 in total

Review 1.  Withdrawal of Antidementia Drugs in Older People: Who, When and How?

Authors:  Carole Parsons
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

2.  The Ethics of Deprescribing in Older Adults.

Authors:  Emily Reeve; Petra Denig; Sarah N Hilmer; Ruud Ter Meulen
Journal:  J Bioeth Inq       Date:  2016-07-14       Impact factor: 1.352

3.  A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.

Authors:  Brenna N Renn; Ali Abbas Asghar-Ali; Stephen Thielke; Angela Catic; Sharyl R Martini; Brian G Mitchell; Mark E Kunik
Journal:  Am J Geriatr Psychiatry       Date:  2017-10-10       Impact factor: 4.105

4.  Factors associated with success in transition care services among older people in Australia.

Authors:  Monica Cations; Catherine Lang; Maria Crotty; Steven Wesselingh; Craig Whitehead; Maria C Inacio
Journal:  BMC Geriatr       Date:  2020-11-23       Impact factor: 3.921
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.